Experienced in Vitrectomy

Lei Zheng

Holistic Medicine
Office
5572 Capital Center Dr, 
Raleigh, NC 
Experienced in Vitrectomy
Office
5572 Capital Center Dr, 
Raleigh, NC 
OverviewInsuranceLocationsClinical Research

Overview

Lei Zheng is a Holistic Medicine provider in Raleigh, North Carolina. Ms. Zheng is rated as an Experienced provider by MediFind in Vitrectomy. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, Upper Tract Urothelial Carcinoma (UTUC), Gallbladder Disease, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Her clinical research consists of co-authoring 1207 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Vitrectomy.

Specialties
Holistic Medicine
Licenses
Acupuncturist in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
5572 Capital Center Dr, Raleigh, NC 27606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).
A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, CCR2/CCR5 dual antagonist, GVAX
Study Phase: Phase 1/Phase 2
A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, GVAX pancreatic cancer, Nivolumab, Urelumab
Study Phase: Phase 2
A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene Given Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Surgically Resected Pancreatic Adenocarcinoma
A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene Given Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Surgically Resected Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Biological, Drug
Study Drug: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine
Study Phase: Phase 2
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Radiation
Study Phase: Phase 2
A Multicenter, Single-blind, Pair-matched, Observational Clinical Trial of LUNSAFE
A Multicenter, Single-blind, Pair-matched, Observational Clinical Trial of LUNSAFE
Enrollment Status: Completed
Publish Date: March 21, 2025
Intervention Type: Diagnostic test, Procedure
A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas
A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: September 05, 2024
Intervention Type: Radiation, Drug
Study Drugs: Cyclophosphamide, GVAX, Pembrolizumab
Study Phase: Phase 2
View 5 Less Clinical Trials

1206 Total Publications

A case report of appendiceal desmoid fibromatosis with chronic appendicitis
A case report of appendiceal desmoid fibromatosis with chronic appendicitis
Journal: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Published: November 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zheng's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile